Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by increased frequency of bowel movements, bleeding, and urgency.1 It is primarily managed by different formulations of mesalamine with some patients requiring more potent immunosuppressive therapy.2 The first of these to be approved were antagonists to tumor necrosis factor (anti-TNF) followed by those to α4β7 integrin.3–5 However, a sizable proportion of patients either do not respond to these agents, or over time fail to maintain a sustained response. The gene discussed is TNF; the disease is ulcerative colitis.